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Abstract
Ecological observations suggest an inverse relationship between smoking in pregnancy and celiac disease (CD) in offspring. 
While individual-level analyses have been inconsistent, they have mostly lacked statistical power or refined assessments of 
exposure. To examine the association between pregnancy-related smoking and CD in the offspring, as well as its consistency 
across data sets, we analyzed: (1) The Norwegian Mother and Child Cohort (MoBa) of 94,019 children, followed from birth 
(2000–2009) through 2016, with 1035 developing CD; (2) a subsample from MoBa (381 with CD and 529 controls) with 
biomarkers; and (3) a register-based cohort of 536,861 Norwegian children, followed from birth (2004–2012) through 2014, 
with 1919 developing CD. Smoking behaviors were obtained from pregnancy questionnaires and antenatal visits, or, in the 
MoBa-subsample, defined by measurement of cord blood cotinine. CD and potential confounders were identified through 
nationwide registers and comprehensive parental questionnaires. Sustained smoking during pregnancy, both self-reported and 
cotinine-determined, was inversely associated with CD in MoBa (multivariable-adjusted [a] OR = 0.61 [95%CI, 0.46–0.82] 
and aOR = 0.55 [95%CI, 0.31–0.98], respectively); an inverse association was also found with the intensity of smoking. 
These findings differed from those of our register-based cohort, which revealed no association with sustained smoking during 
pregnancy (aOR = 0.97 [95%CI, 0.80–1.18]). In MoBa, neither maternal smoking before or after pregnancy, nor maternal or 
paternal smoking in only early pregnancy predicted CD. In a carefully followed pregnancy cohort, a more-detailed smoking 
assessment than oft-used register-based data, revealed that sustained smoking during pregnancy, rather than any smoking 
exposure, predicts decreased likelihood of childhood-diagnosed CD.
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Introduction
Celiac disease (CD) is an autoimmune small-intestinal 
disorder prevalent in 1–3% of children in Western popu-
lations [1, 2]. In CD, genetic and environmental factors 
interplay in causing a loss of immune tolerance to gluten 
[3]. Human leukocyte antigens (HLA) are the primary 
genetic determinants of CD. Besides gluten ingestion, lit-
tle is known about environmental triggers of CD.
Smoking in pregnancy has a profound impact on fetal 
development, including impaired growth and a multitude 
of effects on the immune system [4–6]. In recent decades, 
diminishing smoking rates among pregnant women have 
been observed in many countries [7], while the seropreva-
lence of CD has doubled [8, 9]. However, this inverse eco-
logical relationship has not been supported by individual-
level data which have shown a positive or no association, 
with one exception [10] (previous studies are summarized 
in Supplementary Table 1) [11–16].
This inconsistency of previous research could be owing 
to methodological restrictions, such as crude exposure 
assessments (e.g., “smoking/non-smoking”) which do not 
differ based on the intensity and duration of smoking in 
pregnancy [12–16]. No previous CD study has investi-
gated the risk in relation to cotinine measurements [17], 
a biomarker of nicotine exposure; such an assessment 
could be important as women may underreport smoking 
in pregnancy. In 2014, our research group found a marked 
decreased risk of CD in children whose mothers smoked 
in pregnancy [10]. However, that study was restricted to 
self-reported smoking and had fewer means to assess the 
potential of confounding. Unraveling the link between 
intrauterine smoking exposure and childhood CD is impor-
tant as it may hold clues to the pathogenesis of the disease.
The objective of this study was to examine if maternal 
smoking in pregnancy (measured by self-report and cord 
blood cotinine levels) was associated with CD diagnosis in 
her child. Secondary analyses considered paternal smoking 
and maternal smoking before or after pregnancy, which 
helps to evaluate potential confounding effects from fam-
ily characteristics.
Methods
This study is part of the Norwegian Mother and Child Cohort 
Study (MoBa), a population-based pregnancy cohort study 
[18]. Pregnant women were recruited across Norway in the 
years 1999–2008, and 41% of eligible women participated. 
The present study used prospective parent-reported smoking 
data on 94,019 children in MoBa and measurements of cord 
blood cotinine for a case–control sample nested within the 
cohort. In a separate analysis we assessed maternal smoking 
in a register-based cohort of 536,861 Norwegian children 
(Fig. 1, flowchart).
Study samples
MoBa pregnancy cohort and nested case–control sample
Out of a cohort of 94,019 children in MoBa, 1035 children 
(1.1%) were diagnosed with CD by December 31, 2016. 
Nested within MoBa we designed a case–control study 
using stored cord blood samples from 381 children with CD 
diagnosed by the end of 2013 and 529 randomly selected 
controls without the disease (Fig. 1). We defined CD as 
minimum two records of the International Classification 
of Diseases (ICD)-10 code K90.0 in the Norwegian Patient 
Register (NPR) or CD reported by parental questionnaires 
administered at child’s age 7 years. Since January 1st, 2008, 
the NPR contains individual-level diagnostic data on virtu-
ally all inpatient and hospital-based outpatient care in Nor-
way. We have previously described the identification of CD 
using the NPR [19]. While this register will identify children 
diagnosed prior to 2008 (start of NPR) provided they are 
followed as recommended in the outpatient clinic, data on 
parent reported CD enabled us to identify MoBa-children 
without such a follow-up. Out of 1035 MoBa-children with 
CD, 18 (1.7%) were identified solely based on parent reports 
and had no record of CD in the NPR (an additional 9 chil-
dren who were included based on parent reports had a single 
entry of CD in the NPR).
We choose to define CD as at least two records of the 
disease in NPR in order to rule out children who during work 
up for the disease receive a preliminary working diagnosis of 
CD while waiting for histological or serological confirma-
tion of the disease. We have previously validated CD in the 
MoBa cohort and found that > 92% of the diagnoses were 
confirmed by the parents [20].
Register‑based cohort
Using the Medical Birth Registry of Norway [21] we iden-
tified children born between 2004 and 2012 (n = 536,861; 
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Fig. 1). Out of these, 1919 children (0.4%) were diagnosed 
with CD by December 31, 2014, as defined by repeated 
ICD-10 codes of CD in the NPR. This register-based anal-
ysis was carried out in order to facilitate the comparison 
of our results with those of previous register-based studies 
[12–15]. However, these data were collected independently 
of MoBa resulting in a different follow-up length across 
cohorts. Data on parent reports of CD were not available 
in our register-based cohort.
Fig. 1  Study design and formation of study samples. In the Norwe-
gian Mother and Child Cohort (MoBa) follow-up was conducted with 
parental questionnaires (denoted “Q”) at 18 and 30 gestational weeks 
(GW) and at child’s age 6 months and 7 years. Samples of cord blood 
(denoted “B”) were collected at birth. ANorwegian children born 
in 2004–2012 and who survived the first 6 months of life. BA sin-
gle record of celiac disease (CD) in the Norwegian Patient Register 
(NPR). CMinimum two entries of CD in NPR by December 31, 2014. 
DChildren who survived the first year of life. EA single record of CD 
in NPR (without questionnaire confirmation). FMinimum two records 
of CD in NPR by December 31, 2013, or confirmed through paren-
tal questionnaires. GAmong 113,053 children in MoBa we randomly 
selected 1009 controls; out of these, 11 children had CD and were 
reclassified as cases and two were excluded due to an unconfirmed 
CD diagnosis. HMissing cord blood samples or exposed to moist snuff 
in pregnancy. IMinimum two records of CD in NPR by December 
31, 2016, or confirmed through parental questionnaires. Out of 1035 
children with CD, 18 (1.7%) were identified solely based on parent 
reports and had no record of CD in the NPR (an additional 9 children 
who were included based on parent reports had a single entry of CD 
in the NPR)
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Exposures
MoBa pregnancy cohort: questionnaire data on parental 
smoking
Data on smoking were collected from questionnaires admin-
istered around weeks 18 and 30 of pregnancy (covering the 
period before pregnancy through pregnancy week 17 and 
pregnancy weeks 18–30, respectively) and at child’s age 
6 months (smoking after pregnancy week 30 and up until 
child’s age 6 months). Mothers reported ever-smoking, 
smoking in the last 3 months before pregnancy, smoking 
duration in pregnancy and her average daily number of 
cigarettes smoked. The mother also described the father’s 
smoking habits as smoking/non-smoking before or during 
pregnancy, respectively. Prenatal exposure to environmental 
tobacco smoke (ETS) was quantified by the average number 
of hours per day of pregnancy the mother was exposed to 
secondhand smoke. Postnatal ETS exposure was quantified 
by the average sum of daily cigarettes smoked by the mother 
and father in the child’s first 6 months of life [22]. Excerpts 
of questionnaires are available as Supplementary Material.
To reduce the impact of erroneously registered data, 
discrepancies in smoking exposure as defined by different 
questionnaire items were treated as missing. The mothers of 
191 children had inconsistencies regarding never-smoking 
status or pregnancy-related smoking; information on pater-
nal smoking in pregnancy, as reported by the mother, was 
inconsistent for 5290 children. Never-smoking mothers and 
those not smoking in early pregnancy were assumed continu-
ing as nonsmokers in later pregnancy when such data were 
missing. The primary exposure was maternal smoking in 
pregnancy. To aid causal inference, paternal smoking and 
maternal smoking before or after pregnancy were examined 
as negative controls.
Nested case–control sample: cotinine in cord blood
For a case–control sample nested within MoBa, we retrieved 
stored umbilical-cord plasma for measurements of cotinine, 
a nicotine metabolite, which as detected in cord blood is con-
sidered the gold standard of measuring fetal tobacco expo-
sure at the end of pregnancy [17]. As previously described 
[23], cord blood was collected in EDTA tubes and shipped 
to the MoBa Biobank where plasma was separated before 
storage at − 80 °C. Samples were then thawed and, blinded 
to case–control status, shipped in one batch to the Bevital 
laboratory (Bergen, Norway) where cotinine was measured 
using liquid chromatography-tandem mass spectrometry 
[24]. Based on previous literature [25], we defined children 
with plasma cotinine ≥ 30 nmol/L as being exposed to daily 
maternal smoking in pregnancy. Children with cotinine 
concentrations ranging from 1.0 nmol/L (limit of detection) 
through 29 nmol/L were regarded as exposed to ETS or to 
occasional maternal smoking and children with undetect-
able cotinine concentrations were defined as not exposed 
to smoke.
Register‑based cohort: maternal smoking recorded 
in the Medical Birth Registry of Norway
Information on maternal smoking (current non-smoker, 
occasional and daily smoker) was collected and recorded 
in maternal pregnancy records around 10 and 36 weeks of 
pregnancy as part of the universally accessible antenatal care 
[26]. Mothers may decline to register smoking status. The 
smoking data in the Medical Birth Registry of Norway have 
been extensively studied and demonstrated expected associa-
tions with multiple outcomes [26–30].
Other variables
Based on previous literature and available data we prese-
lected adjustment variables of maternal, paternal and child 
characteristics that may affect a possible association between 
pregnancy-related smoking and CD diagnosis in offspring 
(see directed acyclic graph [Supplementary Figure  1]) 
[31–34]. Variables were categorized as shown in Tables 1, 
2 and Supplementary Table 2. For each child, we retrieved 
sex, birth weight, gestational age, delivery mode, paren-
tal age at delivery, maternal diabetes and parity from the 
Medical Birth Registry of Norway and maternal education 
level as recorded by Statistics Norway. For MoBa-children 
pregnancy questionnaires provided data on parental income, 
occupation and cohabitation [35–37], paternal education 
level and maternal infections in pregnancy [20], while the 
child’s infection frequency by age 6 months and breastfeed-
ing duration were collected from the 6-month questionnaire 
[32, 34]. Data on parental CD and type 1 diabetes were 
retrieved from the NPR (ICD-10 codes K90.0 and E10, 
respectively). Based on previous literature [38], we did not 
consider age at infant gluten introduction as a predictor for 
CD. For our analysis on cotinine we used information on the 
degree of visual hemolysis of all cord blood samples (see our 
previous publication for details [39]).
Genotyping for celiac disease‑associated risk markers
In our nested case–control analysis of cord blood cotinine we 
accounted for the child’s HLA genotype classified as confer-
ring a high risk for CD (DQ2.5/DQ2.5 or DQ2.5/DQ2.2), 
moderate risk (DQ2.5/X or at least one of DQ2.2 or DQ8) 
and a low risk (any other genotype) [40]. We computed a 
non-HLA genetic risk score for CD defined as the child’s 
sum of 44 risk alleles that previously have been linked to CD 
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at genome wide significance [40–42]. Genotyping details are 
available as Supplementary Material.
Statistical analyses
To reduce the impact of missing data on our results we con-
ducted multiple imputation by chained equation [43, 44], 
imputing 25 datasets. Multiple imputation replaces missing 
values with plausible numbers derived from distributions 
of and relationships among observed variables in the data; 
the subsequent analyses thus account for some of the uncer-
tainty of the missing data. We imputed missing information 
on all covariates and exposure variables in MoBa and the 
register-based cohort (range of missingness, 0.1–19%; Sup-
plementary Tables 2 and 3). Our imputation model included 
the child’s CD status and selected covariates. Imputation 
methods consisted of predictive mean matching and logis-
tic models, as appropriate. The results presented are from 
the multiple imputation analyses. Complete-case analyses, 
which ignore observations with incomplete covariates, are 
provided in Supplementary Figures 2 and 3.
We estimated odds ratios (ORs) for CD using logistic 
regression with robust variance estimates allowing for 
cluster-correlated data among siblings [45]. We primar-
ily examined the association between maternal smoking in 
pregnancy, defined by questionnaire data, register-based data 
or cotinine cut-offs, and offspring CD. Because the fetal sus-
ceptibility to smoke changes during the course of pregnancy 
[46], we examined the CD risk according to exposure only in 
early pregnancy (≤ 17 pregnancy weeks) or in early and late 
pregnancy (≥ 18 pregnancy weeks, henceforth referred to as 
sustained smoking during pregnancy). The mother’s average 
number of cigarettes per day of pregnancy was analyzed as 
continuous and trichotomous variables (0 [no use]; 1–2; > 2 
cigarettes per day). Secondary analyses considered paternal 
smoking and maternal smoking before or after pregnancy. 
We performed explorative analyses in MoBa examining the 
effect of timing of maternal smoking cessation and using 
smoking data recorded in the Medical Birth Registry of Nor-
way. To test if any differences found in results across cohorts 
may be explained by the inclusion of parent reported CD 
in MoBa we performed a sensitivity analysis excluding 27 
children with CD identified through parent reports.
All analyses were adjusted for calendar year of birth 
(model I) because of its negative confounding effect on our 
results; younger children were less likely to have developed 
CD and, related to secular trends [7], less likely to have been 
exposed to smoking in pregnancy. In model II we further 
adjusted for maternal education level. We considered model 
II to be our primary adjustment model because it contained 
covariates available in both MoBa and the register-based 
cohort. In MoBa and our nested case–control sample we 
were also able to adjust for parental type 1 diabetes, CD, 
income, occupation, cohabitation and paternal educa-
tion level (model III). The covariates in model I–III were 
all considered to be important confounders. A sensitivity 
analysis considered the effect of additional adjustment for 
mediators (breastfeeding duration, delivery mode, gesta-
tional age and birth weight) and covariates which effect on 
CD where considered to be small (parity, parental age at 
delivery, maternal infections in pregnancy, the child’s infec-
tion frequency by age 6 months) [20, 31]. This sensitivity 
analysis also adjusted for offspring sex. The cotinine analysis 
included the degree of hemolysis of cord blood samples as 
a covariate in models I–III. Finally, we re-ran the analyses 
on cotinine adjusting for HLA and non-HLA genetic risk 
markers for CD. We used Stata 15 (StataCorp, TX) for sta-
tistical analyses.
Ethics
This study was approved by the Regional Committee for 
Medical and Health Research Ethics of southeast Norway 
(reference numbers: 2013/144 and 2013/2114). Informed 
consent was obtained from all individual participants 
included in the study.
Results
MoBa pregnancy cohort: questionnaire data 
on parental smoking
The mothers of 19,773 children (21.0%) reported any smok-
ing during pregnancy. Of these, 12,272 quit smoking before 
18 pregnancy weeks while 7501 continued smoking beyond 
that period. Information independently extracted from the 
Medical Birth Registry of Norway showed that the mothers 
of 10,135 (10.8%) children were smoking around 10 weeks 
of pregnancy. Mothers who smoked were younger, less often 
employed and had a lower education level compared with 
non-smokers (Table 1).
Maternal smoking beyond 18 weeks of pregnancy, but 
not a shorter duration of pregnancy-related smoking, was 
associated with a 40% reduction in risk of CD diagnosis 
in offspring (Fig. 2 [model I]). Results remained essen-
tially unchanged when excluding 27 children with CD 
who were identified through parent reports of CD (data 
not shown). An inverse association was also found with 
the intensity of smoking in pregnancy. These associations 
remained largely unchanged when adjusting for socioeco-
nomic characteristics (Fig. 2 [model III]) and for addi-
tional characteristics linked to smoking and CD diagnosis 
(Supplementary Figure 4). In contrast, neither paternal 
smoking nor maternal smoking before or after pregnancy 
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Table 1  Characteristics of children in the Norwegian Mother and Child Cohort Study (MoBa)
All Maternal smoking in pregnancy
No smoking Smoking < 18 preg. weeks Smoking ≥ 18 preg. weeks
n (%) 94,019 (100) 74,246 (79.0) 12,272 (13.1) 7501 (8.0)
Celiac disease, n (%) 1035 (1.1) 851 (1.1) 132 (1.1) 52 (0.7)
Calendar year of birth, median (range) 2005 (2000–2009) 2005 (2000–2009) 2005 (2000–2009) 2004 (2000–2009)
Girls, n (%) 45,879 (48.8) 36,242 (48.8) 5960 (48.6) 3677 (49.0)
Birth weight (gram), median (IQR) 3600 (3250–3940) 3600 (3260–3940) 3635 (3290–3990) 3498 (3130–3830)
Gestational age (weeks), median (IQR) 40 (39–41) 40 (39–41) 40 (39–41) 40 (39–41)
Cesarean delivery, n (%) 13,903 (14.8) 10,643 (14.3) 2018 (16.4) 1242 (16.6)
Duration of full breastfeeding, n (%)
  < 3 months 31,987 (34.0) 23,682 (31.9) 4872 (39.7) 3433 (45.8)
 3–5 months 27,243 (29.0) 20,814 (28.0) 3886 (31.7) 2543 (33.9)
  ≥ 5 months 34,789 (37.0) 29,750 (40.1) 3514 (28.6) 1524 (20.3)
Child’s infections age 0–6 months, median 
(IQR)
1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2)
Parity, n (%)
 0 [first child] 42,708 (45.4) 32,654 (44.0) 6749 (55.0) 3305 (44.1)
 1 33,255 (35.4) 26,989 (36.4) 3741 (30.5) 2525 (33.7)
  ≥ 2 18,056 (19.2) 14,603 (19.7) 1782 (14.5) 1671 (22.3)
Maternal age at delivery, median (IQR) 30 (27–33) 31 (28–33) 29 (26–32) 29 (25–33)
Maternal education level, n (%)
  ≤ 9 years 7074 (7.5) 3777 (5.1) 1387 (11.3) 1910 (25.5)
10–12 years 27,541 (29.3) 19,203 (25.9) 4780 (39.0) 3557 (47.4)
  ≥ 13 years 59,404 (63.2) 51,266 (69.0) 6105 (49.7) 2034 (27.1)
Maternal occupation, n (%)
 Sick leave/studying 7690 (8.2) 5350 (7.2) 1296 (10.6) 1044 (13.9)
 Unemployed 5854 (6.2) 4221 (5.7) 716 (5.8) 916 (12.2)
 Employed 80,475 (85.6) 64,674 (87.1) 10,260 (83.6) 5541 (73.9)
Maternal annual income (NOK), n (%)
  < 200,000 27,686 (29.4) 19,718 (26.6) 4300 (35.0) 3669 (48.9)
 200,000–399,999 55,425 (59.0) 45,031 (60.7) 6964 (56.8) 3429 (45.7)
  ≥ 400,000 10,908 (11.6) 9497 (12.8) 1008 (8.2) 403 (5.4)
Maternal type 1 diabetes, n (%) 528 (0.6) 400 (0.5) 70 (0.6) 58 (0.8)
Maternal celiac disease, n (%) 1002 (1.1) 827 (1.1) 118 (1.0) 57 (0.8)
Maternal infections in pregnancy, median 
(IQR)
1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2)
Paternal age at delivery, n (%)
  ≤ 29 years 25,563 (27.2) 18,494 (24.9) 4333 (35.3) 2737 (36.5)
30–34 years 36,565 (38.9) 29,693 (40.0) 4499 (36.7) 2373 (31.6)
  ≥ 35 years 31,890 (33.9) 26,060 (35.1) 3440 (28.0) 2391 (31.9)
Paternal education level, n (%)
  ≤ 9 years 10,059 (10.7) 6137 (8.3) 1893 (15.4) 2029 (27.0)
10–12 years 38,009 (40.4) 28,033 (37.8) 5230 (48.3) 4045 (53.9)
  ≥ 13 years 45,951 (48.9) 40,075 (54.0) 4449 (36.3) 1427 (19.0)
Paternal occupation, n (%)
 Sick leave/studying 5142 (5.5) 3732 (5.0) 806 (6.6) 604 (8.1)
 Unemployed 1710 (1.8) 1086 (1.5) 274 (2.2) 350 (4.7)
 Employed 87,167 (92.7) 69,428 (93.5) 11,192 (91.1) 6547 (87.3)
Paternal annual income (NOK), n (%)
  < 200,000 10,619 (11.3) 7423 (10.0) 1730 (14.1) 1465 (19.5)
200,000–399,999 52,250 (55.6) 40,477 (54.5) 7170 (58.4) 4602 (61.4)
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was associated with offspring CD when adjusted for socio-
economic characteristics (Fig. 2).
Nested case–control sample: cotinine in cord blood
Characteristics of the nested case–control sample were 
largely similar to those of the entire MoBa cohort, with the 
exception of a lower cesarean delivery rate (Supplementary 
Table 4). As defined by detectable cord blood cotinine con-
centrations (≥ 1.0 nmol/L), 18.1% (96/529) of randomly 
selected controls were exposed to smoking at the end of 
pregnancy. Notably, in about one-third of these children, nei-
ther parental smoking nor ETS exposure around the time of 
birth were reported in data collected at child’s age 6 months.
Adjusting for birth year, the OR for CD was 0.54 (95% 
CI, 0.31–0.95) for cotinine-determined daily smoking and 
0.84 (95% CI, 0.53–1.33) for occasional smoking/ETS 
exposure at the end of pregnancy, compared with children 
with undetectable cotinine concentrations (“unexposed to 
smoke”). Adjusting for socioeconomic characteristics left 
ORs largely unchanged, albeit with wider CIs (Table 2). A 
similar pattern of results was found in analyses account-
ing for CD-associated genetic risk markers (Supplementary 
Table 5).
Register‑based cohort: maternal smoking recorded 
in the Medical Birth Registry of Norway
Compared with MoBa, the register-based cohort had a lower 
maternal education level (Table 3). The mothers of 72,846 
(13.6%) children were smoking around 10 weeks of preg-
nancy, which was higher compared with the 10.8% maternal 
smoking rate in MoBa at that stage of pregnancy. Adjust-
ing for birth year, children whose mother currently smoked 
around 10 or 36 pregnancy weeks had an OR for CD of 0.89 
(95% CI, 0.72–1.11) and 0.78 (95% CI, 0.65–0.95), respec-
tively, compared with children of non-smoking mothers. The 
inverse association of sustained smoking during pregnancy 
was completely removed when adjusting for maternal educa-
tion level, in contrast to MoBa where we found unchanged 
association pattern before and after adjusting for maternal 
education (Fig. 3).
Table 1  (continued)
All Maternal smoking in pregnancy
No smoking Smoking < 18 preg. weeks Smoking ≥ 18 preg. weeks
  ≥ 400,000 31,150 (33.1) 26,345 (35.5) 3371 (27.5) 1433 (19.1)
Paternal type 1 diabetes, n (%) 609 (0.6) 473 (0.6) 87 (0.7) 49 (0.7)
Paternal celiac disease, n (%) 312 (0.3) 260 (0.3) 28 (0.2) 24 (0.3)
Paternal smoking in pregnancy, n (%) 20,689 (22.0) 10,499 (14.1) 5384 (43.9) 4804 (64.0)
Parental cohabitation, n (%) 90,933 (96.7) 72,597 (97.8) 11,626 (94.7) 6710 (89.4)
Rounded average cell counts and percentages are shown based on results from imputed data
Data from MoBa questionnaires, the Norwegian Patient Registry and the Medical Birth Registry of Norway
IQR, interquartile range; NOK, Norwegian krone, the national currency of Norway; SD, standard deviation
Table 2  Association of cord blood cotinine concentration and childhood celiac disease
A Analysis of trend over categories of increasing cotinine concentrations
All analyses were adjusted for calendar year of birth and degree of hemolysis of cord blood samples (model I). Model II also included maternal 
education level, while model III also accounted for parental type 1 diabetes, celiac disease, income, occupation, cohabitation and paternal educa-
tion level. Missing information on covariates in models II–III imputed by chained Eqs. 
95% CI, 95% confidence interval; aOR, adjusted odds ratio; ETS, environmental tobacco smoke
Celiac disease
n = 381 (%)
Random controls
n = 529 (%)
Model I Model II Model III
aOR 95% CI aOR 95% CI aOR 95% CI
Trichotomous cotinine groups [“Maternal exposure level”]
 Cotinine < 1.0 nmol/L [“No smoke exposure”] 329 (86.4) 433 (81.9) Ref. Ref. Ref.
 Cotinine 1.0–29.9 nmol/L [“ETS/occasional smok-
ing”]
32 (8.4) 49 (9.3) 0.84 0.53–1.33 0.84 0.53–1.35 0.83 0.51–1.36
 Cotinine ≥ 30.0 nmol/L [“Daily smoking”] 20 (5.2) 47 (8.9) 0.54 0.31–0.95 0.55 0.31–0.98 0.60 0.33–1.10
Per change in cotinine  groupA 0.76 0.59–0.97 0.77 0.60–0.98 0.79 0.60–1.03
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Discussion
In Moba, self-reported and cotinine-determined sustained 
smoking during pregnancy, rather than any smoking expo-
sure, were inversely associated with CD diagnosis. These 
findings differed from those of our register-based cohort, 
where we observed no associations with maternal smok-
ing. These inconsistencies in results across closely related 
populations could reflect differences in the detail of smoking 
assessment, that if resolved may shed new light on intrauter-
ine influences on CD development.
Similar to most previous studies we found no association 
between pregnancy-related smoking and offspring CD when 
confined to register-based data on smoking (previous studies 
are summarized in Supplementary Table 1) [12–15]. Gener-
ally, such observations are prone to measurement error by 
relying on dichotomized smoking assessments (e.g., “smok-
ing/non-smoking”) at a single time-point (typically in early 
pregnancy). Consequently, few previous studies have been 
able to differentiate heavy from light smoking or early from 
late pregnancy smoking. Still other studies have relied on 
limited data on potential confounders [11, 12], leaving unan-
swered questions whether those modest relationships found 
were causal, confounded or a coincidence.
Hence, one explanation to our results my be that in using 
MoBa’s more detailed smoking assessments, including coti-
nine-determined smoking status, we were able to unmask a 
true inverse relationship between sustained smoking during 
pregnancy and childhood CD. This association persisted 
after carefully adjustments for a multitude of potential con-
founders. The lack of associations with paternal smoking, 
and maternal smoking before or after pregnancy, do not sup-
port residual confounding by health-affecting family charac-
teristics as a sole cause of our results.
Assuming the observed association to be true, our results 
point towards a role of the intrauterine environment in CD 
etiology. Potential mechanisms warrant further study, but 
may involve programming of the fetal immune system or gut 
development, possibly via differential fetal DNA methyla-
tion [47]. A meta-analysis of the epigenetic effects of mater-
nal smoking on cord blood suggests a possible influence on 
regulatory T-cells [48], which are instrumental in maintain-
ing immune-tolerance. However, nicotine, and many other 
compounds of combustible tobacco products, may also 
directly affect the fetal immune system with implications 
for disease vulnerability later in life [4, 49]. Indeed, both 
experimental and observational studies have shown inverse 
associations between pregnancy-related smoking and child-
hood T1D [50–52], a disease that shares several etiological 
traits with CD [53].
We acknowledge that any potential beneficial effect 
of maternal smoking on offspring CD risk would not 
outweigh the harmful effects of smoking. However, future 
studies investigating the potential mechanisms underly-
ing this association may lead to better understanding of 
the pathogenesis of CD which may, by other means than 
changing smoking advice, lead to methods of disease 
prevention.
Several non-causal explanations can be proposed to 
our finding of an inverse relationship of sustained smok-
ing during pregnancy with CD diagnosed in MoBa, but not 
observed at the national level. As in any observational study 
we cannot rule of that residual or unmeasured confounders, 
such as childhood feeding practices [54], may have influ-
enced our results. On the other hand, the potential effects 
of residual confounding may be less in the socially more 
homogeneous MoBa (Table 1, descriptive characteristics) 
as compared with those of our national register-based cohort 
(Table 3).
Two-thirds of the mothers smoking in early pregnancy, 
often before the pregnancy was confirmed, quit smoking 
during pregnancy. We do not know the extent to which these 
results can be generalized to other populations with different 
smoking habits or if sustained smoking during pregnancy 
may be related to confounding behavioral characteristics not 
captured by our adjustment models or by the use of negative 
controls (e.g. paternal smoking). The participation rate in 
MoBa was 41% which could influence the generalizability 
of those results. A previous comparison between mothers 
enrolling into MoBa and all Norwegian women giving birth 
at that time has shown that the cohort participants were 
older, less likely to have more than two previous births and 
more likely not to smoke during pregnancy (differences that 
were also revealed between MoBa and our register-based 
cohort) [55]. Such differences in prevalence estimates were 
not found to significantly influence exposure-outcome asso-
ciations between participants in MoBa and the general popu-
lation [55].
This study has several strengths, including its large sam-
ple sizes that gave precise relative risk estimates. The lon-
gitudinal data collection of smoking before CD was diag-
nosed in the child minimizes the risk of recall bias. We also 
took advantage of smoking data collected from independent 
sources, self-reported and defined by cord blood cotinine 
measurements, which increase the validity of our findings. 
That approach also allowed us in greater detail than previous 
works, to explore the effects of timing, intensity and duration 
of smoking and to disaggregate the effects of pre- and post-
natal smoking exposure. Finally, using both questionnaire 
and register data we were able to comprehensively adjust for 
confounding socioeconomic characteristics.
Among the limitations of this study is that we were only 
able to ascertain diagnosed CD. Hence, we were unable 
to estimate the association of pregnancy-related smoking 
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with subclinical, screening-detected CD. This is an impor-
tant distinction because most children with CD will remain 
undiagnosed [56], and possibly more often so among those 
of low socioeconomic position [57]. Speculatively, a low-
skilled mother, who is more likely to smoke, might also 
be more reluctant or less able to seek medical care and to 
request CD screening of her child. However, the lower CD 
prevalence in the register-based cohort (0.4%), compared 
with MoBa (1.1%), is likely foremost related to its shorter 
follow-up rather than lower ascertainment of CD (the CD 
prevalence in MoBa has increased with longer follow-up 
[10]). The coverage of CD diagnosis in NPR (launched in 
2008) may in fact be higher for the register-based cohort 
(born in 2004–2012) than for the older cohort of children 
in MoBa (born in 2000–2009). Although, the effects of 
sustained smoking during pregnancy was consistent across 
MATERNAL SMOKING
Ever smoked
Never-smoker
Ever-smoker
Smoking 0-3 months before pregnancy
No smoking
Smoking
Smoking in pregnancy
No smoking
Smoking
Duration of smoking in pregnancy 
No smoking
Smoking <18 preg. weeks
Smoking ≥18 preg. weeks
Amount of daily smoking in pregnancy
Per cigarette
0 [no smoking]
≤2 cigarettes
>2 cigarettes
Timing of smoking cessation [explorative analysis]
Never-smoker
Cessation before pregnancy
Smoking <18 preg. weeks
Smoking ≥18 preg. weeks
PATERNAL SMOKING
Smoking before pregnancy 
No smoking
Smoking
Smoking in pregnancy
No smoking
Smoking
ENVIRONMENTAL TOBACCO SMOKE (ETS)
Prenatal exposure to ETS
Per daily hours of ETS
Not exposed
Exposed
Postnatal exposure to ETS 
Not exposed
Moderately exposed
Highly exposed
560  (54.1)
475  (45.9)
772  (74.6)
263  (25.4)
829  (80.1)
206  (19.9)
851  (82.2)
132  (12.8)
52  (5.0)
973  (94.0)
27  (2.6)
35  (3.4)
560  (67.5)
64  (7.7)
160  (19.3)
45  (5.5)
776  (75.0)
259  (25.0)
835  (80.7)
200  (19.3)
915  (88.4)
120  (11.6)
849  (82.0)
89  (8.6)
97  (9.4)
47,281  (50.8)
45,703  (49.2)
67,037  (72.1)
25,947  (27.9)
71,906  (77.3)
21,078  (22.7)
73,395  (78.9)
12,140  (13.1)
7449  (8.0)
84,325  (90.7)
3149  (3.8)
5020  (5.5)
47,197  (64.1)
5329  (7.2)
14,371  (19.5)
6707  (9.1)
67,957  (73.1)
25,028  (26.9)
72,497  (78.0)
20,487  (22.0)
79,237  (85.2)
13,747  (14.8)
71,990  (77.4)
9687  (10.4)
11,307  (12.2)
No celiac disease
n=92,984 (%)
Celiac disease
n=1035 (%)
0.4 0.6 0.8 1.0 1.2 1.4
 Model I:    aOR  (95%CI)
Model III:  aOR  (95%CI)
Ref.
0.88  (0.77-0.99)
Ref.
0.88  (0.76-1.02)
Ref.
0.85  (0.72-0.99)
Ref.
0.94  (0.78-1.13)
0.60  (0.45-0.80)
0.92  (0.87-0.97)
Ref.
0.66  (0.45-0.98)
0.59  (0.42-0.83)
Ref.
1.01  (0.77-1.32)
0.94  (0.79-1.12)
0.57  (0.42-0.77)
Ref.
0.90  (0.78-1.04)
Ref.
0.85  (0.72-1.00)
0.98  (0.96-0.99)
Ref.
0.75  (0.62-0.92)
Ref.
0.78  (0.62-0.99)
0.73  (0.58-0.90)
Ref.
0.89  (0.78-1.01)
Ref.
0.90  (0.77-1.04)
Ref.
0.86  (0.73-1.01)
Ref.
0.94  (0.78-1.14)
0.61  (0.46-0.82)
0.92  (0.87-0.97)
Ref.
0.67  (0.45-0.99)
0.60  (0.42-0.86)
Ref.
1.01  (0.78-1.33)
0.95  (0.79-1.13)
0.58  (0.42-0.80)
Ref.
0.92  (0.79-1.07)
Ref.
0.86  (0.73-1.02)
0.98  (0.97-1.00)
Ref.
0.77  (0.63-0.94)
Ref.
0.79  (0.62-1.00)
0.74  (0.59-0.92)
Ref.
0.92  (0.81-1.05)
Ref.
0.94  (0.81-1.10)
Ref.
0.90  (0.77-1.07)
Ref.
0.99  (0.81-1.20)
0.64  (0.48-0.86)
0.93  (0.88-0.98)
Ref.
0.68  (0.46-1.01)
0.64  (0.45-0.92)
Ref.
1.07  (0.82-1.41)
0.99  (0.82-1.19)
0.63  (0.45-0.87)
Ref.
0.97  (0.83-1.13)
Ref.
0.91  (0.77-1.09)
0.98  (0.97-1.00)
Ref.
0.80  (0.65-0.98)
Ref.
0.81  (0.64-1.03)
0.80  (0.64-1.01)
Model I
aOR (95% CI)
Model II
aOR (95% CI)
Model III
aOR (95% CI)
Fig. 2  Association of parental smoking and childhood celiac disease 
in the MoBa cohort. Missing covariate and exposure information 
imputed by chained equations. All analyses were adjusted for cal-
endar year of birth (model I). Model II also included maternal edu-
cation level, while model III in addition to previous covariates also 
accounted for parental type 1 diabetes, celiac disease, income, occu-
pation, cohabitation and paternal education level. Explorative analysis 
based on 74,433 children with data on timing of maternal smoking 
cessation. Inconsistent smoking exposure were treated as missing; the 
mothers of 191 children had inconsistencies regarding never-smoking 
status or pregnancy-related smoking; information on paternal smok-
ing in pregnancy, as reported by the mother, was inconsistent for 
5290 children. 95% CI, 95% confidence interval; aOR, adjusted odds 
ratio
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subgroups of varying follow-up time in MoBa (data not 
shown) these differences in follow-up time, as well as in 
the used definitions of CD, make results not directly com-
parable across cohorts.
Notably, in one-third of children with detectable cord 
blood cotinine concentrations, neither parental smoking 
nor ETS exposure around the time of birth were reported. 
This inconsistency may not only reflect differences in the 
method used to define smoking exposure but also differences 
in terms of when such data were collected; while cotinine 
was measured in cord blood collected at birth, self-reported 
smoking data of that time were retrieved from questionnaires 
administered at child’s age 6 months. However, the consist-
ency in our ORs for CD according to cotinine-defined and 
self-reported duration of smoking in MoBa argues against 
that selective missingness of reported smoking may have 
caused spurious results.
Finally, we also acknowledge that missing covariate and 
exposure information is a potential, but unverifiable, source 
of bias. To reduce the risk of such bias, we applied multiple 
imputation; this approach provides valid estimates given 
missingness in itself is unrelated to why observations are 
missing (i.e., missing at random).
In conclusion, sustained smoking during pregnancy, 
rather than any smoking exposure, was inversely associ-
ated with CD diagnosis in MoBa. Causality cannot be 
ascertained. However, in the context of detailed exposure 
assessments and comprehensive adjustment models these 
results may shed new light on intrauterine influences on CD 
development.
Table 3  Characteristics of register-based cohort
A Duration of smoking in pregnancy divided into mutually exclusive groups: no smoking, smoking up to 10 pregnancy weeks and continued 
smoking until 36 pregnancy weeks
B Children whose mothers started smoking in late pregnancy based on results from imputed data
Rounded average cell counts and percentages are shown based on results from imputed data
Data from the Norwegian Patient Registry and the Medical Birth Registry of Norway
IQR interquartile range
All Maternal smoking in  pregnancyA
No smoking Smoking 10 preg. weeks Smoking 36 preg. weeks Inconsistent  dataB
n (%) 536,861 (100) 462,816 (86.2) 27,331 (5.1) 45,514 (8.5) 1199 (0.2)
Celiac disease, n (%) 1919 (0.4) 1667 (0.4) 106 (0.4) 143 (0.3) 4 (0.3)
Calendar year of birth, 
median (IQR)
2008 (2004–2012) 2008 (2004–2012) 2007 (2004–2012) 2008 (2004–2012) 2008 (2004–2012)
Girls, n (%) 261,281 (48.7) 225,263 (48.7) 13,317 (48.7) 22,137 (48.6) 564 (47.1)
Birth weight (g), median 
(IQR)
3530 (3180–3880) 3550 (3200–3890) 3540 (3180–3890) 3355 (3000–3700) 3460 (3110–3800)
Gestational age (weeks), 
median (IQR)
40 (39–41) 40 (39–41) 40 (39–41) 39 (38–40) 40 (38–40)
Cesarean delivery, n (%) 90,021 (16.8) 76,993 (16.6) 4904 (17.9) 7905 (17.4) 219 (18.3)
Parity, n (%)
 0 [first child] 226,246 (42.1) 192,051 (41.5) 15,416 (56.4) 18,323 (40.3) 455 (38.0)
 1 191,690 (35.7) 168,788 (36.5) 7705 (28.2) 14,751 (32.4) 447 (37.3)
   ≥ 2 118,924 (22.2) 101,977 (22.0) 4210 (15.4) 12,440 (27.3) 297 (24.8)
Maternal age at delivery, 
median (IQR)
30 (26–33) 30 (27–34) 27 (23–32) 28 (23–32) 29 (25–33)
Maternal education level, n (%)
  ≤ 9 years 92,526 (17.2) 63,393 (13.7) 7767 (28.4) 20,989 (46.1) 377 (31.5)
10–12 years 160,207 (29.8) 130,971 (28.3) 10,960 (40.1) 17,818 (39.1) 459 (38.3)
  ≥ 13 years 284,127 (52.9) 268,453 (58.0) 8604 (31.5) 6707 (14.7) 363 (30.3)
Maternal diabetes, n (%)
 Pre-gestational 3990 (0.7) 3359 (0.7) 215 (0.8) 408 (0.9) 8 (0.7)
 Gestational 8433 (1.6) 7304 (1.6) 434 (1.6) 672 (1.5) 22 (1.9)
Paternal age at delivery, 
median (IQR)
32 (29–37) 33 (29–37) 30 (26–35) 31 (26–36) 31 (27–36)
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